Eytan Ben‐Ami

1.5k total citations
25 papers, 877 citations indexed

About

Eytan Ben‐Ami is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Eytan Ben‐Ami has authored 25 papers receiving a total of 877 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 7 papers in Molecular Biology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Eytan Ben‐Ami's work include CAR-T cell therapy research (9 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Melanoma and MAPK Pathways (4 papers). Eytan Ben‐Ami is often cited by papers focused on CAR-T cell therapy research (9 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Melanoma and MAPK Pathways (4 papers). Eytan Ben‐Ami collaborates with scholars based in Israel, United States and Spain. Eytan Ben‐Ami's co-authors include Jacob Schachter, Gal Markel, Michal J. Besser, Orit Itzhaki, Ronnie Shapira‐Frommer, Adva Kubi, Avraham J. Treves, Noa Shoshani, Bruria Shalmon and Daphna Levy and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Eytan Ben‐Ami

25 papers receiving 859 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eytan Ben‐Ami Israel 11 508 323 229 206 86 25 877
Bruce A. Robbins United States 17 271 0.5× 287 0.9× 126 0.6× 192 0.9× 52 0.6× 26 963
Christy Ralph United Kingdom 14 455 0.9× 185 0.6× 336 1.5× 332 1.6× 116 1.3× 46 801
Silvia Calpe Netherlands 16 196 0.4× 574 1.8× 109 0.5× 180 0.9× 74 0.9× 27 904
Chang‐Ho Jeon South Korea 13 189 0.4× 175 0.5× 103 0.4× 169 0.8× 68 0.8× 56 592
Magesh Sathaiah United States 11 393 0.8× 134 0.4× 145 0.6× 159 0.8× 29 0.3× 14 794
David Vicente Spain 14 455 0.9× 89 0.3× 459 2.0× 82 0.4× 45 0.5× 30 726
Alessia Piermattei Italy 15 128 0.3× 72 0.2× 48 0.2× 115 0.6× 63 0.7× 49 535
Wing Y. Chan China 15 345 0.7× 167 0.5× 152 0.7× 150 0.7× 86 1.0× 25 802
Di Long China 11 140 0.3× 290 0.9× 82 0.4× 136 0.7× 43 0.5× 22 560
Tomomitsu Doi Japan 15 127 0.3× 326 1.0× 78 0.3× 271 1.3× 38 0.4× 29 661

Countries citing papers authored by Eytan Ben‐Ami

Since Specialization
Citations

This map shows the geographic impact of Eytan Ben‐Ami's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eytan Ben‐Ami with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eytan Ben‐Ami more than expected).

Fields of papers citing papers by Eytan Ben‐Ami

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eytan Ben‐Ami. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eytan Ben‐Ami. The network helps show where Eytan Ben‐Ami may publish in the future.

Co-authorship network of co-authors of Eytan Ben‐Ami

This figure shows the co-authorship network connecting the top 25 collaborators of Eytan Ben‐Ami. A scholar is included among the top collaborators of Eytan Ben‐Ami based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eytan Ben‐Ami. Eytan Ben‐Ami is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Levin, Yotam, et al.. (2021). Ethics and execution of developing a 2nd wave COVID vaccine – Our interim phase I/II VSV-SARS-CoV2 vaccine experience. Vaccine. 39(21). 2821–2823. 7 indexed citations
2.
Melero, Ignacio, Ravit Geva, Eytan Ben‐Ami, et al.. (2021). MO24-1 Phase I/IIa trial evaluating safety and clinical activity of DuoBody®-PD-L1×4-1BB (GEN1046) in advanced solid tumors. Annals of Oncology. 32. S313–S313. 4 indexed citations
3.
Garralda, Elena, Ravit Geva, Eytan Ben‐Ami, et al.. (2020). 412 First-in-human phase I/IIa trial to evaluate the safety and initial clinical activity of DuoBody®-PD-L1×4–1BB (GEN1046) in patients with advanced solid tumors. SHILAP Revista de lepidopterología. A250.2–A251. 6 indexed citations
4.
Zer, Alona, Eyal Fenig, Sivan Shamai, et al.. (2019). A phase II single arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated Classical Kaposi Sarcoma (CKS). Annals of Oncology. 30. ix135–ix135. 3 indexed citations
5.
Ben‐Ami, Eytan, et al.. (2018). Imatinib-induced drug reaction with eosinophilia and systemic symptoms in solid tumors. Anti-Cancer Drugs. 29(9). 919–923. 6 indexed citations
6.
Papadopoulos, Kyriakos P., Eytan Ben‐Ami, Amita Patnaik, et al.. (2018). Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial. BMC Cancer. 18(1). 790–790. 8 indexed citations
7.
Ben‐Ami, Eytan, Jason L. Hornick, & Andrew J. Wagner. (2018). The potential of emerging new therapeutics for the treatment of perivascular epithelioid cell tumors (PEComa). Expert Opinion on Orphan Drugs. 6(9). 537–543. 4 indexed citations
8.
Ben‐Ami, Eytan, Ying Huang, Prafulla C. Gokhale, et al.. (2018). Abstract 953: LRRC15 is a novel antigen in sarcoma and the therapeutic target of the antibody-drug conjugate (ADC) ABBV-085. Cancer Research. 78(13_Supplement). 953–953. 4 indexed citations
9.
Zippel, Douglas, Gal Markel, Guy Ben‐Betzalel, et al.. (2017). Perioperative BRAF inhibitors in locally advanced stage III melanoma. Journal of Surgical Oncology. 116(7). 856–861. 12 indexed citations
10.
Ben‐Ami, Eytan, Constance M. Barysauskas, Margaret von Mehren, et al.. (2016). Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy. Annals of Oncology. 27(9). 1794–1799. 82 indexed citations
11.
Ben‐Ami, Eytan & Jacob Schachter. (2016). Adjuvant Treatment for Stage III Melanoma in the Era of Targeted Medicine and Immunotherapy. PubMed. 3(2). 137–147. 2 indexed citations
12.
Leibowitz‐Amit, Raya, Ronnie Shapira‐Frommer, Talia Golan, et al.. (2015). 523 Initial clinical experience with pembrolizumab in metastatic heavily pre-treated patients with solid cancers in a single institution. European Journal of Cancer. 51. S111–S111. 1 indexed citations
13.
Galore-Haskel, Gilli, Yael Nemlich, Eyal Greenberg, et al.. (2015). A novel immune resistance mechanism of melanoma cells controlled by the ADAR1 enzyme. Oncotarget. 6(30). 28999–29015. 54 indexed citations
14.
Ben‐Ami, Eytan, et al.. (2014). Involvement of the Family Physician in the Care of Chemotherapy-Treated Patients With Cancer: Patients' Perspectives. Journal of Oncology Practice. 10(5). 298–305. 22 indexed citations
15.
Besser, Michal J., Ronnie Shapira‐Frommer, Orit Itzhaki, et al.. (2013). Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies. Clinical Cancer Research. 19(17). 4792–4800. 294 indexed citations
16.
Greenberg, Eyal, Michal J. Besser, Eytan Ben‐Ami, et al.. (2013). A comparative analysis of total serum miRNA profiles identifies novel signature that is highly indicative of metastatic melanoma: a pilot study. Biomarkers. 18(6). 502–508. 39 indexed citations
17.
Itzhaki, Orit, Eyal Greenberg, Bruria Shalmon, et al.. (2013). Nicotinamide Inhibits Vasculogenic Mimicry, an Alternative Vascularization Pathway Observed in Highly Aggressive Melanoma. PLoS ONE. 8(2). e57160–e57160. 47 indexed citations
18.
Gutman, Haim, et al.. (2012). Multidisciplinary management of very advanced stage III and IV melanoma: Proof-of-principle. Oncology Letters. 4(2). 307–310. 1 indexed citations
19.
Shapira‐Frommer, Ronnie, Michal J. Besser, Iryna Kuchuk, et al.. (2011). Adoptive transfer of short-term cultured tumor-infiltrating lymphocytes (young TIL) in metastatic melanoma patients.. Journal of Clinical Oncology. 29(15_suppl). 8510–8510. 4 indexed citations
20.
Ben‐Ami, Eytan, Itzhak Levy, Jacob Katz, Ovadia Dagan, & Itamar Shalit. (2008). Risk factors for sternal wound infection in children undergoing cardiac surgery: a case–control study. Journal of Hospital Infection. 70(4). 335–340. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bruce A. Robbins Breakdown of academic impact, for papers by Christy Ralph Breakdown of academic impact, for papers by Silvia Calpe Breakdown of academic impact, for papers by Chang‐Ho Jeon Breakdown of academic impact, for papers by Magesh Sathaiah Breakdown of academic impact, for papers by David Vicente Breakdown of academic impact, for papers by Alessia Piermattei Breakdown of academic impact, for papers by Wing Y. Chan Breakdown of academic impact, for papers by Di Long Breakdown of academic impact, for papers by Tomomitsu Doi
Rankless by CCL
2026